Isabelle Fournier (Presenter)
Laboratoire PRISM U1192, INSERM
Bio: Pr. I. fournier is Deputy Director of PRISM, where she is heading the re-search axis Technological Innovation. IF is a specialist in MS applications in biology and clinics. IF was first in Europe to develop MALDI MS into a molecular imaging technology in 2001, and in 2007 to demonstrate that MALDI IMS could be performed from archived formalin-fixed paraffin-embedded (FFPE) tissue samples. This work was valorized by several patents and lead IF to be co-founder of the start-up company Imabiotech SAS. Since several years, she is working on the development of large scale strategies for spatially re-solved proteomics over limited tissue surface regions, as well as on the development of new in-strumentation for in-vivo real-time MS for guided surgery and diagnostics. She has supervised 17 PhD students, authored 85 publications, 12 book chapters, 10patents, and gave 103 conferences (H-factor 33
Authorship: Isabelle Fournier & Michel Salzer
Laboratoire PRISM, U1192 Inserm, University Lille, 59000 Lille
| Short Abstract One major difficulty of sarcoma is the fact that they have poorly defined margins. In order to improve the diagnosis and better define the margins during the surgery SpiderMass instrument will be used. Classification performance of this novel surgery instrument in pre-operative conditions on fresh biopsies has been tested. A clear differentiation between healthy and cancerous layers of different types of sarcoma have been observed. Specific markers of between tumour and heathy group have been identified by real time MS/MS. Based on such a classification, margins studies have been undertaken and compared to MALDI Mass spectrometry imaging confirming the high accuracy of SpiderMass technology. |
Long Abstract
Introduction
Soft tissue sarcomas account for 15% of skin tumours in dogs and it represent 2.4% of all malignancies in pediatric patients, and about 20% of all primary bone cancers. One major difficulty of sarcoma is the fact that they have poorly defined margins and have finger-like projections that infiltrate between muscles and layers of connective tissues. In order to improve the diagnosis and better define the margins during the surgery SpiderMass instrument will be used.
Methods
SpiderMass is devoted to in vivo classification of cancerous tissues through mass spectrometric analysis based on ambient resonant Infrared Laser Ablation based on the highly effective excitation of O-H bonds in water molecules. A fibered laser ablate in less invasive manner and in real time the surface of the tumour. We tested the classification performance of this novel surgery instrument in pre-operative conditions on fresh biopsies.
Results
A clear differentiation between healthy and cancerous layers of different types of sarcoma have been observed from SpiderMass fingerprint of each tissue types. Sub-classification can be also performed e.g. on osteosarcoma (oesteoblastic, fibroblastic and chondroblastic). Specific markers of between tumour and heathy group have been identified by MS/MS. Based on such a classification, margins studies have been undertaken and compared to MALDI Mass spectrometry imaging associated to histological staining and immunocytochemistry, two pathologist’s standard techniques.
Conclusions & Discussion
Results confirmed the high accuracy of SpiderMass technology to delimitate the borderline tissue on dog sarcoma. In this context, ¨SpideMmass instrument can now a novel instrument used by pathologist for extemporal biopsies analyses and guide surgeons during operation as we performed in veterinary operating room.
References & Acknowledgements:
This research was supported by grants from the Ministère de L’Education Nationale, de L’Enseignement Supérieur et de la Recherche, ANR (IF), Région Haut de France (O’DREAMS (IF, MS, DT), the Université de Lille (MD) SIRIC ONCOLille (IF, MD), Grant INCa-DGOS-Inserm 6041aa, the CCMIC and INSERM.
| Description | Y/N | Source |
| Grants | no | |
| Salary | no | |
| Board Member | no | |
| Stock | no | |
| Expenses | no |
IP Royalty: no
| Planning to mention or discuss specific products or technology of the company(ies) listed above: | no |